FDA-TRACK: Center for Biologics Evaluation and Research - Goal 4
FDA's Center for Biologics Evaluation and Research (CBER) regulates biological products for human use under applicable federal laws, including the Public Health Service Act and the Federal Food, Drug and Cosmetic Act. CBER protects and advances the public health by ensuring that biological products are safe and effective and available to those who need them. CBER also provides the public with information to promote the safe and appropriate use of biological products.
CBER leadership understands the Center cannot accomplish mission-critical initiatives without an aligned strategy and organizational accountability. To manage for strategic excellence and organizational accountability, CBER relies on the Offices that provide internal program support. These Offices work collaboratively to advance and maintain a skilled and experienced workforce adaptable to an everchanging environment.
Goal 4: Manage for Strategic Excellence and Organizational Accountability
Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons.